Summary
Danaher Corporation's 2019 10-K filing highlights a year of strategic expansion and operational focus. The company reported a 5.0% increase in consolidated sales to $17.9 billion, driven by a 6.0% core sales growth, indicating strong underlying performance across its Life Sciences, Diagnostics, and Environmental & Applied Solutions segments. A significant event was the pending $21 billion acquisition of GE Biopharma, which was expected to close in Q1 2020 and positioned Danaher for substantial growth in the life sciences sector. The company also completed the disposition of its Dental business (Envista) through an IPO and split-off, generating proceeds that were used to manage its capital structure. Danaher continued to emphasize its Danaher Business System (DBS) for operational improvements and demonstrated a commitment to innovation through research and development investments. The financial outlook appears robust, with increasing sales and operating profit, despite investments related to the large GE Biopharma acquisition and other strategic initiatives. The company managed its debt effectively, even as it incurred additional debt to finance the GE Biopharma acquisition. Danaher's diversified business model across multiple industries and geographies provided resilience against market fluctuations. Investors should note the ongoing integration of acquired businesses and the strategic importance of the GE Biopharma acquisition for future growth and market positioning.
Financial Highlights
54 data points| Revenue | $17.91B |
| Cost of Revenue | $7.93B |
| Gross Profit | $9.98B |
| R&D Expenses | $1.13B |
| SG&A Expenses | $5.59B |
| Operating Income | $3.27B |
| Interest Expense | $108.00M |
| Net Income | $3.01B |
| EPS (Basic) | $4.11 |
| EPS (Diluted) | $4.05 |
| Shares Outstanding (Basic) | 715.00M |
| Shares Outstanding (Diluted) | 725.50M |
Key Highlights
- 1Consolidated sales increased by 5.0% to $17.91 billion in 2019, with core sales growing by 6.0%.
- 2The company announced and proceeded with the significant acquisition of GE Biopharma for approximately $21.0 billion, expected to close in Q1 2020, bolstering the Life Sciences segment.
- 3Danaher completed the disposition of its Dental business (Envista Holdings Corporation) through an IPO and subsequent split-off, generating proceeds used for debt management and corporate purposes.
- 4Operating profit increased to $3.27 billion, with operating profit margins improving to 18.3% from 17.9% in the prior year.
- 5The company maintained a strong cash flow from operations, providing flexibility for investments, acquisitions, and returns to shareholders.
- 6Total debt increased significantly to $21.73 billion, primarily due to financing for the GE Biopharma acquisition, while the company maintained its credit facilities.
- 7The company's strategic focus remains on enhancing its portfolio through capital allocation, strengthening competitive advantage via DBS, and attracting talent.